Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation

Journal of Neurochemistry

Volumn 72, Issue 4, 1999, Pages 1773-1776

  Reynolds, Gavin P ^a   Dalton, Caroline F ^a   Tillery, Claire L ^a   Mangiarini, Laura ^b   Davies, Stephen W ^c   Bates, Gillian P ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Catecholamines; GABA; Huntington's disease; Neurodegeneration; Transgenic mice

Indexed keywords

4 AMINOBUTYRIC ACID; CATECHOLAMINE; NEUROTRANSMITTER; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CELL CULTURE; DATA ANALYSIS; DOPAMINE BLOOD LEVEL; GENE EXPRESSION; HISTOPATHOLOGY; HUNTINGTON CHOREA; MOUSE; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PURKINJE CELL; SEROTONIN BLOOD LEVEL; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUNTINGTON DISEASE; HYDROXYINDOLEACETIC ACID; MICE; MICE, TRANSGENIC; MUTATION; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NOREPINEPHRINE; NUCLEAR PROTEINS; SEROTONIN; TRINUCLEOTIDE REPEATS;

ANIMALIA; MUS MUSCULUS;

EID: 0033066942     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.721773.x     Document Type: Article

References (23)

1. Cha J. H., Kosinski C. M., Kerner J. A., Alsdorf S. A., Mangiarini L., Davies S. W., Penney J. B., Bates G. P., and Young A. B. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. USA 95, 6480-6485.
2. Cross A. J., Slater P., and Reynolds G. P. (1986) Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. Neurosci. Lett. 67, 198-202.
3. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L., and Bates G. P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548.
4. Davies S. W., Beardsall K., Turmaine M., DiFiglia M., Aronin N., and Bates G. P. (1998) Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 351, 131-133.
5. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P., and Aronin N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuntes in brain. Science 277, 1990-1993.
6. Dure L. S., Young A. B., and Penney J. B. (1991) Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann. Neurol. 30, 785-793.
7. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Forntali M., Folstein S., Ross C., Franz M., and Abbott M. (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4, 387-392.
8. Fonnum F. (1984) Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42, 1-11.
9. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
10. Jeste D. V., Barban L., and Parisi J. (1984) Reduced Purkinje cell density in Huntington's disease. Exp. Neurol. 85, 78-86.
11. Kish S. J., Robitaille Y., El-Awar M., Clark B., Schut L., Ball M. J., Young L. T., Currier R., and Shannak K. (1992) Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 42, 1573-1577.
12. Kish S. J., Guttman M., Robitaille Y., El-Awar M., Chang L.-J., and Levey A. I. (1997) Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1. Neurology 48, 1109-1111.
13. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W., and Bates G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
14. Paulson H. L., Perez M. K., Trottier Y., Trojanowski J. Q., Subramony S. H., Das S. S., Vig P., Mandel J.-L., Fischbeck K. H., and Pittman R. N. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19, 333-344.
15. Pearson S., Czudek C., Mercer K., and Reynolds G. P. (1991) Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatograpny of stable o-phthalaldehyde-sulphite derivatives. J. Neural Transm. Gen. Sect. 86, 151-157.
16. Perry T. L., Hansen S., and Kloster M. (1973) Huntington's chorea: deficiency of gamma-aminobutyric acid in brain. N. Engl. J. Med. 288, 337-342.
17. Reynolds G. P. and Dalton C. F. (1998) Transgenic models and subcellular pathology - do they tell us what goes wrong in Huntington's disease? Mol. Psychiatry 3, 192-195.
18. Reynolds G. P. and Garrett N. J. (1986) Striatal dopamine and homovanillic acid in Huntington's disease. J. Neural Transm. 65, 151-155.
19. Reynolds G. P. and Pearson S. J. (1987) Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neurosci. Lett. 78, 233-238.
20. Reynolds G. P. and Pearson S. J. (1990) Brain GABA levels in asymptomatic Huntington's disease. N. Engl. J. Med. 323, 682.
21. 3H]L-689,560 binding to the glycine site of the glutamate/NMDA receptor in the brain in Huntington's disease. J. Neurol. Sci. 125, 46-49.
22. Robitaille Y., Schut L., and Kish S. J. (1995) Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype. Acta Neuropathol. (Berl.) 90, 572-581.
23. Weeks R. A., Piccini P., Harding A. E., and Brooks D. J. (1996) Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 40, 49-54.